bioRxivCell BiologyPreprint
Conformation governs cellular behaviors of LRRK2 Parkinson's disease variants
Kathryn S HatchiD, Katherine J SurridgeiD, Wei GaiiD, Brookelyn QuaniD, Gaurav KumariD, Nicholas LattaliD, Robert AbrischiD, Niels PaganiiD, Andres E LeschzineriD, Samara L Reck-PetersoniD
Abstract
Gain-of-function of leucine-rich repeat kinase 2 (LRRK2) is a common cause of Parkinson's disease (PD). In its autoinhibited state, the leucine-rich repeats of LRRK2 block the kinase active site, preventing substrate phosphorylation. Displacing the repeats ('unlatching') primes LRRK2 for activity. Preferential unlatching causes increased substrate phosphorylation of the PD allele LRRK2[R1441H], but not LRRK2[G2019S]. Here, we define a large class of PD-associated 'unlatching' mutations based on their effect on LRRK2 conformation. Unlatching mutants show increased localization to membranes, the site of LRRK2's Rab substrates. Unlatching mutants are also characterized by decreased LRRK2 S935 phosphorylation, which we define as a biomarker of conformation. This framework resolves the mechanism of variants such as I2020T, which structural studies could not predict. Overall, we establish unlatching as a unifying mechanism for most PD-linked variants and describe measurable readouts for identifying LRRK2-driven disease.
- organism: human
- assay: proteomics
- research focus: protein structure prediction
- research focus: protein design
- research focus: drug response / drug discovery
- research focus: variant effect prediction
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Impact of 100 LRRK2 variants linked to Parkinsons Disease on kinase activity and microtubule binding
Alexia F. Kalogeropulou, Elena Purlyte, … Dario R. Alessi·Biochemical JournalPeer-reviewed·Aug 11, 2022
- A revised 1.6 Å structure of the GTPase domain of the Parkinson’s disease-associated protein LRRK2 provides insights into mechanisms
C.-X. Wu, J. Liao, … Q. Q. Hoang·bioRxiv·Jun 23, 2019
- The structural basis for LRRK2's activation and autoinhibition
Amalia C. Villagran Suarez, Kathryn S. Hatch, … Andrés E. Leschziner·CellPeer-reviewed·Aug 10, 2026
- LRRK2 exonic variants associated with Parkinson’s disease augment phosphorylation levels for LRRK2-Ser1292 and Rab10-Thr73
Kenneth V. Christensen, Morten Hentzer, … Garrick P. Smith·bioRxiv·Oct 22, 2018
- 14-3-3 binding maintains the Parkinson's associated kinase LRRK2 in an inactive state
Juliana A. Martinez Fiesco, Alexandra G. Beilina, … Ping Zhang·Nature CommunicationsPeer-reviewed·Aug 5, 2025
- Parkinson's disease-associated LRRK2 risk variant, G2385R, enhances Rab substrate phosphorylation and impairs neuronal integrity
An Phu Tran Nguyen, Roger Moser, … Darren J. Moore·Human Molecular GeneticsPeer-reviewed·Jan 1, 2026